The 2020 updates to the NCCN Guidelines for Rectal Cancer incorporated novel diagnostic clarifications and therapeutic strategies. Neoadjuvant therapy remains a cornerstone for localized disease management. Emerging biomarker-targeted therapies have shown promise in metastatic colorectal cancer treatment. This review synthesizes the updated guidelines, highlighting the integration of precision medicine approaches in rectal cancer care, and discusses implications for clinical practice and future research directions.